Loading...
Loading...
CYTH| Name | Value |
|---|---|
| Revenues | 186.8K |
| Cost of Revenue | 15.8K |
| Gross Profit | 171.0K |
| Operating Expense | 5,143.7K |
| Operating I/L | -4,972.6K |
| Other Income/Expense | -7.8K |
| Interest Income | 0.0K |
| Pretax | -4,980.4K |
| Income Tax Expense | -169.4K |
| Net Income/Loss | -4,811.0K |
Cyclo Therapeutics, Inc. is a clinical stage biotechnology company specializing in cyclodextrin-based products for treating Niemann-Pick Type C disease and Alzheimer's disease. Its lead drug candidate, Trappsol Cyclo, is in Phase III clinical trials for Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to pharmaceutical, nutritional, and other industries for use in diagnostics and specialty drugs.
